Back to search

France· FR:61430397

RIVASTIGMINE EG LABO 9,5 mg/24 h, patch transdermique

A rivastigmine product containing rivastigmine, registered in France by EG LABO - LABORATOIRES EUROGENERICS. The same ATC class is registered in 18 of our 19 countries.

ATC N06DA03

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedRIVASTIGMINE EG LABO 9,5 mg/24 h, pat…ATCN06DA03REGISTER NO.FR:61430397PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Rivastigmine is registered in 18 of 19 countries.

Countries holding a registration under ATC N06DA03 (rivastigmine), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 11 of them publish a price we can compare per daily dose

Rivastigmine · ATC N06DA03

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivastigmine costs, country by country.

Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.042 in Czechia to $2.19 in Italy — a ×52 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Rivastigmine · price per daily dose (9 mg)

USD · FX 28 Sept 2026

  • IT Italy$2.19
  • CH Switzerland$1.33
  • CZ Czechia$0.042
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
RIVASTIGMINE
Manufacturer
EG LABO - LABORATOIRES EUROGENERICS
Country
France (FR)
ATC code
N06DA03
ATC class
Rivastigmine
Defined daily dose
9 mg, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930243015
    30 sachet(s) papier polytéréphtalate (PET) aluminium polyacrylonitrile avec fermeture de sécurité enfant de 1 patch transdermique

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

235 interactions on record for rivastigmine.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rivastigmine · interactions on record

235 records

  • 8 severe
  • 166 moderate
  • 59 info

Most severe, free to view

  • OzanimodL04AA38severe
  • SiponimodL04AA42severe
  • OzanimodL04AE02severe
  • SiponimodL04AE03severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rivastigmine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rivastigmine products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

  • Austria · Nimgista, Rivagelan
  • Belgium · Rivastigmin Sandoz, Rivastigmine Viatris
  • Bulgaria · Ридаксин
  • Germany · Demelora, Rivastigmin
  • Denmark · Rigmin, Rivastigmin Orion
  • Spain · Alzerta, Alzerta Dos Por Semana
  • Finland · Rivastigmin Orion, Rivastigmine Sandoz
  • United Kingdom (Northern Ireland) · Almuriva, Alzest
  • Greece · Alapril, Balaxon
  • Iceland · Exelon, Nimvastid
  • Italy · Demelora, Rivastigmina Aurobindo
  • Liechtenstein · Exelon, Rivastigmine 1 A Pharma
  • Malta · Rivastigmine Aurobindo
  • Netherlands · Ristidic, Rivastgimine Neuraxpharm
  • Norway · Exelon, Nimvastid
  • Poland · Atmina, Evertas
  • Portugal · Nervopan, Rivastigmina Alter
  • Romania · Evertas, Ridaxin
  • Sweden · Rigmin, Rivastigmin Orion
  • Slovenia · Rivastigmin Teva, Rivastigmin Teva B.V.
  • Slovakia · Ristidic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b610aead-180f-405c-9135-c7943afa8f34
GET /v1/drugs/b610aead-180f-405c-9135-c7943afa8f34?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61430397",
  "date_amm": "2021-11-26",
  "type_amm": "Procédure de reconnaissance mutuelle",
  "numero_ue": null,
  "substance": "RIVASTIGMINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "patch",
  "voies_administration": "transdermique",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about rivastigmine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.